Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Sutro Biopharma, Inc. reported a quarterly loss of $0.91 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.63, representing an earnings surprise of -44.44% [1] - The company posted revenues of $17.4 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 25.83%, compared to revenues of $13.01 million in the same quarter last year [2] - Over the last four quarters, Sutro Biopharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Sutro Biopharma shares have declined approximately 46% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.53 on revenues of $13.6 million, and for the current fiscal year, it is -$2.06 on revenues of $53.34 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Sutro Biopharma belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Sutro Biopharma's stock performance [5][6]